Submission of 33rd Annual Report including the Notice of AGM for the financial year 2024-25 under Regulation 34 of SEBI (LODR), Regulation, 2015
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.8 pts less than Nifty Microcap 250 and 4.4 pts less than its Software Products peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Hindustan Bio Sciences Limited has filed its 33rd Annual Report and AGM Notice for FY 2024-25, with the AGM scheduled for Tuesday, 30th September 2025 at 10:00 AM at its Hyderabad registered office. Revenue from operations fell to Rs. 81.33 lakhs from Rs. 105.27 lakhs in the previous year, a decline of roughly 23%, while total expenses also dropped to Rs. 71.51 lakhs from Rs. 100 lakhs. Net profit rose to Rs. 10.07 lakhs (from Rs. 5.76 lakhs) and EPS improved to Rs. 0.10 (from Rs. 0.06), helped by lower costs. The company's reserves remain negative at around Rs. (1.14 crore) and no dividend has been recommended. The AGM will consider re-appointment of director Mr. Jason Jeorge (who retires by rotation) and the appointment of Mr. VBSS Prasad as Secretarial Auditor for a 5-year term from FY 2025-26 to FY 2029-30. The statutory auditor's report carries no qualifications or adverse remarks.
Profit growth on the back of cost cuts masks a weak top-line and persistently negative reserves, signalling the company remains a very small player with limited financial cushion. Clean audit report is a positive, but shareholders should track whether revenue can stabilise before relying on the improved earnings.